In China, women of childbearing age, who constitute a major demographic of online consumers and professionals in emerging industries are increasingly experiencing significant sleep disturbances. Existing studies have predominantly focused on the association between sleep disorders and polycystic ovary syndrome, often overlooking the independent impact of sleep patterns on ovulatory function in the general population of women attempting conception. Specifically, the synergistic effect of blue light exposure from electronic devices and delayed sleep onset remains underexplored, and evidence regarding the relationship between sleep duration, sleep quality and ovulation rates is insufficient. The primary objective of this study is to investigate the association between sleep habits and ovulation rates among Chinese women with fertility intentions. Second, it aims to determine the correlation between these sleep habits and factors such as screen time, night shift work and regional differences. Third, using a user-friendly sleep monitoring wristband, the study seeks to clarify the quantitative relationship between objective sleep parameters (eg, sleep onset time, sleep efficiency) and ovulation rates in this population.

This is a 1.5-year multicentre prospective cohort study. Participants will be recruited from at least five reproductive medicine centres in mainland China between May 2025 and December 2026. The study will enrol women aged 20–50 years with fertility intentions. Baseline demographic information and habitual sleep patterns will be assessed through standardised questionnaires, with participants self-reporting their sleep conditions. Prepregnancy biochemical indicators and anthropometric data will be recorded. The primary outcome will be the ovulation rate, with secondary outcomes including pregnancy rate and miscarriage rate.

This research project has been approved by the Clinical Research Ethics Committee of Guangdong Provincial Maternal and Child Health Hospital (Approval No.20250072), and has also received approval from the Primary and Specialty Nursing Committee for implementation and development. All participants will be informed verbally and in writing about the study procedures and objectives prior to signing the consent form. Data confidentiality will be ensured, and participants may withdraw their consent at any stage of the research. The findings will be presented at international conferences and published in peer-reviewed scientific journals.

Intermittent theta-burst stimulation (iTBS) is a non-invasive brain stimulation technique that has been shown to improve cognition and mood when applied to certain brain structures and regions. Despite research demonstrating that iTBS may have clinical utility in treating cognitive and mood changes, no study has yet been conducted to explore the potential to modulate the neurophysiological changes that can underpin cognitive and mood changes during the menopause transition. Cognitive and psychological symptoms are commonly reported by females experiencing the menopause transition, and it is thought that these symptoms arise due to various neurophysiological, metabolic and endocrinological changes. Despite being common, there is a lack of treatments available for managing these symptoms and a scarcity of data regarding the mechanisms by which they occur.

The aim of this 5-week randomised, sham-controlled, double-blinded pilot clinical trial (n=72) is to assess the underlying mechanisms of action of iTBS in females in the late menopause transition and the relationship with cognition and mood. Data will be analysed using Stata^TM. Normality checks will guide the choice between parametric and non-parametric tests. Generalised linear models will assess within-subject and between-subject effects across timepoints, with additional regression analyses exploring associations between biomarkers, cognition and mood. Effect sizes, CIs and relevant test statistics will be reported, with significance set at p

The study protocol has been reviewed and ethically approved by the Western Sydney University Human Research Ethics Committee (H16200; 8 November 2024). All participants will provide written informed consent prior to enrolment. Results from this trial will be disseminated via peer-reviewed publications and conference presentations, with findings shared in accordance with open science and data transparency principles.

ACTRN12625000030471, Australian New Zealand Clinical Trials Registry

This study examines the incidence and risk factors of euglycaemic diabetic ketoacidosis (euDKA) in patients undergoing coronary artery bypass grafting (CABG) and evaluates their postoperative outcomes over a 6-month follow-up period.

This study is a single-centre, nested case-control study, conducted in Tianjin, China.

An international cardiovascular hospital.

A total of 1524 patients, with a mean age of 64 (9) years, who underwent isolated elective CABG surgery were reviewed.

Data were extracted from electronic medical records. EuDKA cases were identified by reviewing laboratory examination results until discharge, including arterial blood gas analysis and urine samples. Logistic regression analysis was used in a case-control design to identify potential risk factors of sodium-glucose cotransporter 2 inhibitor (SGLT2i)-associated euDKA. Post-discharge follow-up was conducted through regular outpatient visits.

15 patients with euDKA, all with type 2 diabetes, were identified post-surgery, 13 of whom were SGLT2i users. The cumulative incidence of euDKA within 7 days after surgery was 1% in the cohort, increasing to 7.6% among those who discontinued SGLT2i 1–6 days (n=171) before surgery. A case-control study added seven additional confirmed euDKA patients to the case group, resulting in 20 cases and 95 controls. Univariate regression analysis revealed that the risk of euDKA was 7.304 times higher (95% CI 2.517 to 21.197; p–1 (OR: 6.882, 95% CI 1.822 to 25.997; p=0.004) were associated with a higher risk of euDKA. Compared with controls, euDKA patients experienced a higher rate of type 5 myocardial infarction (6/20 (30%) vs 9/95 (9.5%); p=0.035) and recurrent ketosis post-discharge (3/19 (15.8%) vs 0/87 (0%); p=0.005).

This cohort study highlights a notable incidence of euDKA following CABG, particularly among patients using SGLT2i. Close monitoring in the ICU is recommended for patients with intraoperative abnormal blood glucose and pH levels to prevent euDKA.